Purple Biotech Ltd ADR (PPBT) Stock Price, Quote & News

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 933 3121

Fax: 972 3 509 7196

Website: purple-biotech.com

Address:

4 Oppenheimer Street, Science Park, Rehovot, Israel

Winorbust Jul. 22 at 11:55 PM

$PPBT this is the funniest post of the month so far. Smitty is dumb enough to agree with all of that.

0 · Reply

Smittysixty Jul. 22 at 8:36 PM

$PPBT Big Pharma doesn’t need any more data to make a move — Purple walked into BIO with full CM‑24 Phase 2, full NT‑219 Phase 1/2, years of NT‑157 lineage work, fresh CAPTN‑3 platform data, and a Stage 1 pass for NT‑219’s Phase 2. That’s the exact evidence package mid‑phase oncology buyouts are based on. Mechanism validated, human signal confirmed, platform scalable, and multiple assets aligned with pharma’s patent‑cliff needs. If a company wanted the whole pipeline, BIO was more than enough to make that decision.

1 · Reply

Purplepayday Jul. 22 at 7:20 PM

$PPBT i just want you to know this: The earth is flat, and it’s hollow ! .. The moon is not real, it’s just holistic! They have genocided all real birds between 1959 and 1971, replacing them with surveillance drones that recharge on power lines ! ..… If you think that i’m right about that, then read Smitty’s post‘s also…. 👍

0 · Reply

StocHolliday Jul. 22 at 6:59 PM

$PPBT absolutely fucking pathetic

2 · Reply

Smittysixty Jul. 22 at 6:26 PM

$PPBT Big Pharma will typically wait until a drug clears Stage 1 of a Simon two‑stage Phase 2 before acquiring it — in fact, that’s one of the most common acquisition checkpoints in oncology. Stage 1 is the futility gate, the moment where a drug proves it has real biological activity in humans. Before that, pharma watches. After that, pharma evaluates. Passing Stage 1 doesn’t guarantee an acquisition, but it does move NT‑219 into the zone where buyouts typically happen: early efficacy signal confirmed, mechanism validated, and risk meaningfully reduced. That’s why so many mid‑phase oncology deals happen right after Stage 1 — it’s the point where the science becomes real and the upside becomes worth paying for.

1 · Reply

Smittysixty Jul. 22 at 6:23 PM

$PPBT Interesting update on the NT‑219 Phase 2 listing. The primary completion date jumped from 6/12/26 → 2/1/30 — not because of a delay, but because Simon two‑stage trials only extend the timeline when Stage 1 passes. If Stage 1 had failed, the trial would’ve stopped early and the 2026 date would’ve stayed. http://ClinicalTrials.gov requires sponsors to update the primary completion date once a study moves into full Stage 2 follow‑up, and that’s exactly what this change reflects. And no — companies aren’t required to put out a press release for passing Stage 1. They are required to update the registry. That update is the signal.

0 · Reply

Smittysixty Jul. 22 at 6:20 PM

$PPBT 27k in volume — that’s nearly 2% of the entire float. Someone’s clearly accumulating at these levels despite the trolls doing their best to distract by promising "future lower discounts.” These levels appear to be good enough for a lot of investors.

0 · Reply

mymoneybackppbt Jul. 22 at 1:40 PM

$PPBT I'll buy 1.09

2 · Reply

Stocktelligence Jul. 22 at 1:26 PM

$PPBT

0 · Reply

coinspitter Jul. 22 at 10:39 AM

$PPBT

0 · Reply

Purple Biotech presents new IM1240 data at EACR

2026-05-20T21:35:38.000Z - 2 months ago

Purple Biotech files $200M mixed securities shelf

2026-04-27T11:44:09.000Z - 3 months ago

Purple Biotech reports IM1240 demonstrates potent anti-tumor activity

2026-03-25T12:17:12.000Z - 4 months ago

Purple Biotech announces collaboration with Converge Bio

2026-03-17T11:31:37.000Z - 4 months ago

Purple Biotech regains compliance with Nasdaq

2026-03-13T17:47:18.000Z - 4 months ago

Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright

2026-03-13T12:13:32.000Z - 4 months ago

Purple Biotech CEO Gil Efron to step down in August

2026-03-13T12:07:41.000Z - 4 months ago

Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year

Fri, 13 Mar 2026 08:04:00 -0400 - 4 months ago

Purple Biotech Announces CEO Transition

2026-02-28T00:50:34.000Z - 5 months ago

Purple Biotech trading halted, news pending

2026-02-25T22:35:50.000Z - 5 months ago

Purple Biotech to implement ADS ratio change

Wed, 25 Feb 2026 16:20:00 -0500 - 5 months ago

Purple Biotech Announces Plan to Implement ADS Ratio Change

2026-01-07T13:05:42.000Z - 7 months ago

Purple Biotech completes toxicology study of IM1240

2025-12-11T12:26:28.000Z - 7 months ago

Purple Biotech’s antibody platform shows anti-tumor activity

Dec 4, 2025, 7:00 AM EST - 8 months ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

2025-11-14T13:11:08.000Z - 8 months ago

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

2025-11-14T13:10:49.000Z - 8 months ago

Purple Biotech sees cash runway into 1H27

Nov 14, 2025, 8:00 AM EST - 8 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

2025-10-29T13:21:27.000Z - 9 months ago

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

2025-10-29T11:41:23.000Z - 9 months ago

Purple Biotech achieves manufacturing milestone for IM1240

Oct 29, 2025, 7:33 AM EDT - 9 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

2025-10-20T20:05:22.000Z - 9 months ago

Purple Biotech receives noncompliance notification from Nasdaq

Oct 20, 2025, 4:00 PM EDT - 9 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

2025-09-10T12:10:31.000Z - 11 months ago

Purple Biotech receives intention to grant a European patent covering NT219

Sep 5, 2025, 4:00 PM EDT - 11 months ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

2025-09-04T13:20:09.000Z - 11 months ago

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

2025-09-04T11:20:09.000Z - 11 months ago

Purple Biotech announces new data on IM1240

PPBT

2025-09-03T11:06:00.000Z - 11 months ago

Purple Biotech expands CAPTN-3 portfolio with IM1305

PPBT

2025-08-29T13:20:14.000Z - 11 months ago

Purple Biotech files to sell 2.7M American Depositary Shares, warrants

PPBT

Aug 27, 2025, 7:00 AM EDT - 11 months ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

2025-08-06T11:21:25.000Z - 1 year ago

Purple Biotech reports Q2 EPS 40c vs $1.80 last year

PPBT

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

May 21, 2025, 7:10 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2025 Financial Results

May 12, 2025, 7:30 AM EDT - 1 year ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Apr 28, 2025, 8:28 AM EDT - 1 year ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 18, 2024, 6:30 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Aug 30, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 8:12 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 25, 2024, 7:35 AM EDT - 2 years ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 10, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 2, 2024, 4:00 PM EDT - 2 years ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 2 years ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jun 27, 2024, 7:45 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

May 21, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports First Quarter 2024 Financial Results

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 3:55 PM EDT - 2 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 3 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 6, 2023, 7:50 AM EDT - 3 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 3, 2023, 7:50 AM EDT - 3 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Aug 22, 2023, 9:29 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Jul 11, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 18, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Winorbust Jul. 22 at 11:55 PM

$PPBT this is the funniest post of the month so far. Smitty is dumb enough to agree with all of that.

0 · Reply

Smittysixty Jul. 22 at 8:36 PM

1 · Reply

Purplepayday Jul. 22 at 7:20 PM

0 · Reply

StocHolliday Jul. 22 at 6:59 PM

$PPBT absolutely fucking pathetic

2 · Reply

Smittysixty Jul. 22 at 6:26 PM

1 · Reply

Smittysixty Jul. 22 at 6:23 PM

0 · Reply

Smittysixty Jul. 22 at 6:20 PM

0 · Reply

mymoneybackppbt Jul. 22 at 1:40 PM

$PPBT I'll buy 1.09

2 · Reply

Stocktelligence Jul. 22 at 1:26 PM

$PPBT

0 · Reply

coinspitter Jul. 22 at 10:39 AM

$PPBT

0 · Reply

GoldmanSlaps Jul. 22 at 3:49 AM

$PPBT man what a failure this turned into

0 · Reply

65creedmore Jul. 22 at 2:49 AM

$PPBT 11/2 where did they hide all the shares? Criminal

1 · Reply

Winorbust Jul. 21 at 8:47 PM

$PPBT that is so insane, you have severe mental issues. There’s countless stocks that are American or European or Chinese that are just as much of a scam as this stock has been. Capitalism doesn’t make someone a crook. There’s tons of Jewish companies that provide good and services that are not crooks. Crooks can be in all nationalities and all religions. Look at the “crooks” in Minnesota that stole $$ billions of tax payer dollars and guess, not Jewish, they were Muslims. Or how about Gavin Newsome and the billions of dollars that disappeared under his watch? Not Jewish.

2 · Reply

Winorbust Jul. 21 at 8:43 PM

$PPBT Smitty has been saying the same thing for years. All while the stock -Reverse split- 3 times and crashed 4 times. It’s now heading for under $1 -again- and then another reverse split. Like I predicted, we will probably only see $4.20s for the 4th time, after another reverse split. Oh and the prices he’s talking about didn’t mean anything back with the warrant exercise prices that our management lowered so that the institutions stayed ok. Lol He keeps talking about “troll narratives” but in over 5 years, how many times has Smitty been right? -Zero- How many times have the bears been right? 100% of the time

0 · Reply

Smittysixty Jul. 21 at 5:02 PM

$PPBT Across the industry, over $300B in revenue is at risk from patent cliffs. That’s why 2026 M&A is exploding — big pharma isn’t browsing, they’re racing. Purple’s pipeline sits directly in the strike zone: • resistance‑reversal • next‑gen checkpoint • tri‑specific T/NK engager • investigator‑funded Phase 2 • pivotal‑ready immunotherapy • IND‑ready platform When you overlay Purple’s pipeline with big pharma’s needs, multiple companies make sense — but Merck, BMS, Gilead, and Pfizer stand out.

1 · Reply

Smittysixty Jul. 21 at 5:01 PM

$PPBT Pfizer CEO's could also be an option in an acquisition: Pfizer is facing massive patent losses and has been licensing oncology assets aggressively. They recently executed a $1.25B oncology licensing deal to fill pipeline gaps. Purple fits Pfizer because: • NT‑219 and CM‑24 offer IO combination potential • CAPTN‑3 gives Pfizer a multi‑specific engager platform • Pfizer needs differentiated immunotherapies to stay competitive Pfizer has the cash and the urgency.

0 · Reply

Smittysixty Jul. 21 at 5:00 PM

$PPBT Gilead (Kite Pharma)'a CEO might also Makes Sense Gilead is expanding its oncology footprint and recently bought Arcellx for up to $7.8B. Their strategy is clear: cell‑based and T/NK‑engager innovation. Purple fits Gilead because: • CAPTN‑3 is a tri‑specific T/NK engager • It aligns directly with Kite’s cell‑therapy ecosystem • It gives Gilead a differentiated platform they can scale This is one of the strongest platform‑to‑platform fits.

0 · Reply

Smittysixty Jul. 21 at 5:00 PM

$PPBT Bristol‑Myers Squibb's CEO could also Makes Sense BMS is also staring down major patent cliffs and has been buying differentiated oncology assets early. They acquired RayzeBio for $4.1B to strengthen their IO combinations. Purple fits BMS because: • CM‑24 adds a next‑gen checkpoint option • NT‑219 supports IO durability • CAPTN‑3 gives them a multi‑specific engager platform they currently lack BMS needs fresh IO combinations — Purple has two.

0 · Reply

Smittysixty Jul. 21 at 4:59 PM

$PPBT Someone mentioned the next CEO so I think Merck's CEO makes the most sense. Here's why: Merck faces the biggest patent cliff in the entire industry: Keytruda loses exclusivity in 2028. They’ve been buying oncology assets aggressively to fill that gap. Purple’s pipeline fits Merck perfectly: • NT‑219 → resistance‑reversal (extends IO durability) • CM‑24 → next‑gen checkpoint (Merck needs PD‑1 combo partners) • CAPTN‑3 → tri‑specific T/NK engager (Merck is expanding into cell‑engagers) When you overlay pipelines, Merck is the cleanest strategic match.

1 · Reply

JuggernautRaider Jul. 21 at 4:47 PM

$PPBT who cares. I want them to sell CM24 to my American friends. Gil Efron was a scam artist worse than the $SUNE or $NEXR or $RDHL CEOs… but CM24 could save lives. I intend to do something about it @Duediligence20 instead of complaining Tony ⚾️ 🇺🇸 💥 🏈 ⚾️ 🎇 🏀 🏉 ⚾️

1 · Reply

LetItRip675 Jul. 21 at 4:30 PM

$PPBT I need a cigarette

0 · Reply

PPBTPhoenix Jul. 21 at 4:23 PM

$PPBT Anybody have any thoughts/guesses on next CEO? I imagine he/she will probably come from within Israel, and quite possibly from within the company ( Hadas/Schickler). Hard to find someone outside the company that still believes in this scam (Except for Shitty Smitty). All comments welcome as I am tired of the same repetitive BS on this page for the last few months.

2 · Reply

Market Cap	1.29M
Revenue (ttm)	0.00
Net Income (ttm)	-26.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	33,500
Avg Vol	382,844
Day's Range	N/A - N/A
Shares Out	929,000.00
Stochastic %K	0%
Beta	0.68
Analysts	Sell
Price Target	$30.00